Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20548257 | 1.00 | S1PR4 (0.33) | S1PR4S1PR1LNPEPTLR7S1PR5 | |
| Trifluoroacetic Acid SCHEMBL2197595 | 0.94 | S1PR4 (0.30) | S1PR4S1PR1 | |
| Trifluoroacetic Acid SCHEMBL2202675 | 0.94 | S1PR4 (0.30) | S1PR4S1PR1 | |
| Trifluoroacetic Acid SCHEMBL567278 | 0.94 | S1PR4 (0.30) | S1PR4S1PR1 | |
| Trifluoroacetic Acid SCHEMBL16872584 | 0.90 | S1PR4 (0.32) | S1PR4S1PR1 | |
| Trifluoroacetic Acid SCHEMBL20261710 | 0.90 | — | — | |
| Trifluoroacetic Acid SCHEMBL566660 | 0.90 | — | — | |
| Trifluoroacetic Acid SCHEMBL566855 | 0.85 | — | — | |
| Trifluoroacetic Acid SCHEMBL565836 | 0.83 | S1PR4 (0.33) | S1PR4S1PR1TLR7S1PR5 | |
| SCHEMBL1919728 | 0.83 | MCHR1 (0.33) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10117873-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3336089-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2016-08-11 | — | — | US | disclosed |
| US-9346806-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2016-05-24 | — | — | US | disclosed |
| EP-3000813-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9233962-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2324026-B1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140336175-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8765772-B2 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120035193-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-8067426-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2324025-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | Smithkline Beecham Corporation (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2324026-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | Smithkline Beecham Corporation (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010018131-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018133-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336175-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNAR1, IFNG, STING1 | S1PR4 594/4885S1PR1 291/4885LNPEP 2099/4885 |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNAR1, IFNG, STING1 | S1PR4 594/4885S1PR1 291/4885LNPEP 2099/4885 |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNG, IFNAR1, STING1 | S1PR4 685/4885S1PR1 270/4885LNPEP 2668/4885 |
| US-10117873-B2 | 6-amino-purin-8-one compounds | IFNG, IFNAR1, IRF3 | S1PR4 1947/4885S1PR1 1277/4885LNPEP 1232/4885 |
| US-20120035193-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | S1PR4 1947/4885S1PR1 1277/4885LNPEP 1232/4885 |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | S1PR4 1947/4885S1PR1 1277/4885LNPEP 1232/4885 |
| US-20100075995-A1 | COMPOUNDS | IFNG, IRF3, IFNAR1 | S1PR4 1062/4885S1PR1 613/4885LNPEP 2742/4885 |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | S1PR4 1947/4885S1PR1 1277/4885LNPEP 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.